Last updated on December 2018

Riociguat in Children With Pulmonary Arterial Hypertension (PAH)


Brief description of study

This study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from 6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study consists of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Clinical Study Identifier: NCT02562235

Contact Investigators or Research Sites near you

Start Over

The Children's Hospital

Aurora, CO United States
  Connect »

East Carolina University

Greenville, NC United States
  Connect »

UZ Gent

Gent, Belgium
  Connect »

H pital des Enfants

TOULOUSE Cedex 9, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.